• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Olorofim Susceptibility Testing of 1,423 Danish Mold Isolates Obtained in 2018-2019 Confirms Uniform and Broad-Spectrum Activity.1,423 丹麦霉菌分离株的奥洛福霉素药敏试验证实具有一致和广谱的活性。这些分离株是在 2018-2019 年获得的。
Antimicrob Agents Chemother. 2020 Dec 16;65(1). doi: 10.1128/AAC.01527-20.
2
EUCAST Determination of Olorofim (F901318) Susceptibility of Mold Species, Method Validation, and MICs.EUCAST 测定霉菌种属对奥洛福霉素(F901318)的敏感性、方法验证及 MIC 值。
Antimicrob Agents Chemother. 2018 Jul 27;62(8). doi: 10.1128/AAC.00487-18. Print 2018 Aug.
3
In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates.新型抗真菌化合物 F901318 对难治疗的曲霉属分离株的体外活性。
J Antimicrob Chemother. 2017 Sep 1;72(9):2548-2552. doi: 10.1093/jac/dkx177.
4
In vitro activity of olorofim against 507 filamentous fungi including antifungal drug-resistant strains at a tertiary laboratory in Australia: 2020-2023.澳大利亚三级实验室检测奥洛氟米对 507 株丝状真菌(包括抗真菌药物耐药株)的体外活性:2020-2023 年。
J Antimicrob Chemother. 2024 Oct 1;79(10):2611-2621. doi: 10.1093/jac/dkae267.
5
In vitro activity of the novel antifungal olorofim against dermatophytes and opportunistic moulds including Penicillium and Talaromyces species.新型抗真菌药奥利万星对皮肤癣菌和机会性霉菌(包括青霉属和拟青霉属)的体外活性研究。
J Antimicrob Chemother. 2021 Apr 13;76(5):1229-1233. doi: 10.1093/jac/dkaa562.
6
In vitro activity of olorofim (F901318) against fungi of the genus, Scedosporium and Rasamsonia as well as against Lomentospora prolificans, Exophiala dermatitidis and azole-resistant Aspergillus fumigatus.奥拉罗芬(F901318)对赛多孢子菌属和拉氏菌属真菌以及对多育镰刀菌、皮炎外瓶霉和耐唑类烟曲霉的体外活性。
Int J Antimicrob Agents. 2020 Sep;56(3):106105. doi: 10.1016/j.ijantimicag.2020.106105. Epub 2020 Jul 25.
7
In vitro activity of olorofim against Aspergillus fumigatus sensu lato clinical isolates: activity is retained against isolates showing resistance to azoles and/or amphotericin B.体外研究表明olorofim 对烟曲霉复合体临床分离株具有活性:对表现出唑类和/或两性霉素 B 耐药的分离株仍具有活性。
Clin Microbiol Infect. 2022 Sep;28(9):1291.e7-1291.e10. doi: 10.1016/j.cmi.2022.05.013. Epub 2022 May 18.
8
Mutations, Extrolite Profiles, and Antifungal Susceptibility in Clinical and Environmental Isolates of the Aspergillus viridinutans Species Complex.变异性、外生代谢产物谱和临床及环境曲霉属绿僵菌种复合体分离株的抗真菌药敏性。
Antimicrob Agents Chemother. 2019 Oct 22;63(11). doi: 10.1128/AAC.00632-19. Print 2019 Nov.
9
Resistance profiling of to olorofim indicates absence of intrinsic resistance and unveils the molecular mechanisms of acquired olorofim resistance.对奥洛罗芬的耐药性分析表明不存在固有耐药性,并揭示了获得性奥洛罗芬耐药性的分子机制。
Emerg Microbes Infect. 2022 Dec;11(1):703-714. doi: 10.1080/22221751.2022.2034485.
10
In vitro activity of olorofim (F901318) against clinical isolates of cryptic species of Aspergillus by EUCAST and CLSI methodologies.微量肉汤稀释法和 CLSI 方法检测olorofim(F901318)对曲霉属隐种临床分离株的体外活性。
J Antimicrob Chemother. 2019 Jun 1;74(6):1586-1590. doi: 10.1093/jac/dkz078.

引用本文的文献

1
Invasive Trichoderma longibrachiatum breakthrough infection in a hematology patient.血液学患者发生长枝木霉侵袭性突破性感染。
Med Mycol Case Rep. 2025 Jun 14;49:100709. doi: 10.1016/j.mmcr.2025.100709. eCollection 2025 Sep.
2
EUCAST olorofim MICs for 3,550 Danish mold and dermatophyte isolates from 2020 to 2023.2020年至2023年从丹麦分离出的3550株霉菌和皮肤癣菌的欧盟CAST奥利罗芬最低抑菌浓度。
Antimicrob Agents Chemother. 2025 Aug 6;69(8):e0035325. doi: 10.1128/aac.00353-25. Epub 2025 Jun 26.
3
activity of novel antifungals, natamycin, and terbinafine against .新型抗真菌药、那他霉素和特比萘芬对……的活性
Antimicrob Agents Chemother. 2025 Jun 4;69(6):e0191324. doi: 10.1128/aac.01913-24. Epub 2025 May 15.
4
Antifungal Resistance in Non-fumigatus Aspergillus Species.非烟曲霉属真菌中的抗真菌耐药性
Mycoses. 2025 Apr;68(4):e70051. doi: 10.1111/myc.70051.
5
Trends of Azole-Resistant Aspergillus Fumigatus Susceptibility Over 12 Years from a German ECMM Excellence Center.来自德国欧洲医学真菌学联盟卓越中心的12年间烟曲霉对唑类药物耐药性的变化趋势
Mycopathologia. 2025 Apr 5;190(2):34. doi: 10.1007/s11046-025-00941-x.
6
Refractory versus resistant invasive aspergillosis.难治性与耐药性侵袭性曲霉病
J Antimicrob Chemother. 2025 Mar 14;80(Supplement_1):i9-i16. doi: 10.1093/jac/dkaf003.
7
Clinical significance and antifungal susceptibility profile of 103 clinical isolates of species complex and obtained from NIH patients.从美国国立卫生研究院患者中分离出的103株某菌种复合体的临床分离株的临床意义及抗真菌药敏谱。 (你提供的原文中species complex后面的内容缺失,我按照正常逻辑补充了“某菌种复合体”,你可根据实际情况修改。)
J Clin Microbiol. 2025 Apr 9;63(4):e0155024. doi: 10.1128/jcm.01550-24. Epub 2025 Mar 7.
8
Review of the novel antifungal drug olorofim (F901318).新型抗真菌药物奥利伏非姆(F901318)的综述。
BMC Infect Dis. 2024 Nov 7;24(1):1256. doi: 10.1186/s12879-024-10143-3.
9
Fusarium species,Scedosporium species, and Lomentospora prolificans: A systematic review to inform the World Health Organization priority list of fungal pathogens.镰刀菌属、枝顶孢属和繁茂枝孢菌:为世界卫生组织真菌病原体优先排序提供信息的系统综述。
Med Mycol. 2024 Jun 27;62(6). doi: 10.1093/mmy/myad128.
10
The Role of Olorofim in the Treatment of Filamentous Fungal Infections: A Review of In Vitro and In Vivo Studies.奥洛罗芬在丝状真菌感染治疗中的作用:体外和体内研究综述
J Fungi (Basel). 2024 May 10;10(5):345. doi: 10.3390/jof10050345.

本文引用的文献

1
How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST).如何根据修订后的临床折点 v.10.0 欧洲抗菌药物敏感性试验委员会 (EUCAST) 来解释抗真菌化合物的 MIC 值。
Clin Microbiol Infect. 2020 Nov;26(11):1464-1472. doi: 10.1016/j.cmi.2020.06.007. Epub 2020 Jun 17.
2
Madurella mycetomatis, the main causative agent of eumycetoma, is highly susceptible to olorofim.马杜拉分枝霉菌是真菌性肿廇的主要病原体,对奥利万星高度敏感。
J Antimicrob Chemother. 2020 Apr 1;75(4):936-941. doi: 10.1093/jac/dkz529.
3
A unique multidrug-resistant clonal Trichophyton population distinct from Trichophyton mentagrophytes/Trichophyton interdigitale complex causing an ongoing alarming dermatophytosis outbreak in India: Genomic insights and resistance profile.一种独特的多药耐药性克隆须癣毛癣菌种群,与须癣毛癣菌/趾间毛癣菌复合体不同,导致印度正在发生的令人震惊的皮肤癣菌病爆发:基因组见解和耐药谱。
Fungal Genet Biol. 2019 Dec;133:103266. doi: 10.1016/j.fgb.2019.103266. Epub 2019 Sep 3.
4
Mutations, Extrolite Profiles, and Antifungal Susceptibility in Clinical and Environmental Isolates of the Aspergillus viridinutans Species Complex.变异性、外生代谢产物谱和临床及环境曲霉属绿僵菌种复合体分离株的抗真菌药敏性。
Antimicrob Agents Chemother. 2019 Oct 22;63(11). doi: 10.1128/AAC.00632-19. Print 2019 Nov.
5
Emerging Terbinafine Resistance in : Clinical Characteristics, Squalene Epoxidase Gene Mutations, and a Reliable EUCAST Method for Detection.特比萘芬耐药性的出现:临床特征、角鲨烯环氧化酶基因突变及可靠的 EUCAST 检测方法。
Antimicrob Agents Chemother. 2019 Sep 23;63(10). doi: 10.1128/AAC.01126-19. Print 2019 Oct.
6
EUCAST Susceptibility Testing of Isavuconazole: MIC Data for Contemporary Clinical Mold and Yeast Isolates.EUCAST 伏立康唑药敏试验:当代临床霉菌和酵母分离株的 MIC 数据。
Antimicrob Agents Chemother. 2019 May 24;63(6). doi: 10.1128/AAC.00073-19. Print 2019 Jun.
7
In vitro activity of olorofim (F901318) against clinical isolates of cryptic species of Aspergillus by EUCAST and CLSI methodologies.微量肉汤稀释法和 CLSI 方法检测olorofim(F901318)对曲霉属隐种临床分离株的体外活性。
J Antimicrob Chemother. 2019 Jun 1;74(6):1586-1590. doi: 10.1093/jac/dkz078.
8
Efficacy of Olorofim (F901318) against , , and in Murine Models of Profound Neutropenia and Chronic Granulomatous Disease.氟罗福司汀(F901318)在严重中性粒细胞减少症和慢性肉芽肿病的小鼠模型中对 、 、 的疗效。
Antimicrob Agents Chemother. 2019 May 24;63(6). doi: 10.1128/AAC.00129-19. Print 2019 Jun.
9
Dihydroorotate dehydrogenase inhibitor olorofim exhibits promising activity against all clinically relevant species within Aspergillus section Terrei.二氢乳清酸脱氢酶抑制剂奥洛福米对曲霉菌属 Terrei 亚属内所有临床相关种均表现出有前景的活性。
J Antimicrob Chemother. 2018 Nov 1;73(11):3068-3073. doi: 10.1093/jac/dky329.
10
How to: EUCAST recommendations on the screening procedure E.Def 10.1 for the detection of azole resistance in Aspergillus fumigatus isolates using four-well azole-containing agar plates.方法:EUCAST 关于使用含唑类药物的四孔琼脂平板检测烟曲霉分离株中唑类耐药性的筛选程序 E.Def 10.1 的建议。
Clin Microbiol Infect. 2019 Jun;25(6):681-687. doi: 10.1016/j.cmi.2018.09.008. Epub 2018 Sep 28.

1,423 丹麦霉菌分离株的奥洛福霉素药敏试验证实具有一致和广谱的活性。这些分离株是在 2018-2019 年获得的。

Olorofim Susceptibility Testing of 1,423 Danish Mold Isolates Obtained in 2018-2019 Confirms Uniform and Broad-Spectrum Activity.

机构信息

Unit of Mycology, Statens Serum Institut, Copenhagen, Denmark.

Unit of Mycology, Statens Serum Institut, Copenhagen, Denmark

出版信息

Antimicrob Agents Chemother. 2020 Dec 16;65(1). doi: 10.1128/AAC.01527-20.

DOI:10.1128/AAC.01527-20
PMID:33020160
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7927864/
Abstract

Olorofim is a novel antifungal drug in phase 2 trials. It has shown promising activity against various molds, except for Mucorales. Initially, we observed a broad range of EUCAST MICs for Here, we explored the MIC variability in more detail and prospectively investigated the susceptibility of contemporary clinical mold isolates, as population data are needed for future epidemiological cutoff (ECOFF) settings. Fifteen isolates previously found with low/medium/high MICs (≤0.002 to 0.25 mg/liter) were tested repeatedly and EUCAST MICs read in a blinded fashion by three observers. , encoding the olorofim target enzyme dihydroorotate dehydrogenase (DHODH), was sequenced. A total of 1,423 mold isolates (10 species complexes [including 1,032 isolates] and 105 other mold/dermatophyte isolates) were examined. Olorofim susceptibility (modal MIC, MIC, MIC, and wild-type upper limits [WT-ULs] [species complexes with ≥15 isolates]) was determined and compared to that of four comparators. MICs (mg/liter) were within two 2-fold dilutions (0.016 to 0.03) for 473/476 determinations. The MIC range spanned four dilutions (0.008 to 0.06). No significant mutations were found. Modal MIC/WT-UL (mg/liter) values were 0.03/0.06 ( and ), 0.06/0.125 ( and ), and 0.06/0.25 ( and ). The MIC range for spp. was 0.008 to 0.25. Olorofim susceptibility was similar for azole-resistant and -susceptible isolates of but reduced for and (MICs of >1). With experience, olorofim susceptibility testing is robust. The testing of isolates from our center showed uniform and broad-spectrum activity. Single-center WT-ULs are suggested.

摘要

奥洛福米是一种处于 2 期临床试验阶段的新型抗真菌药物。它对各种霉菌(except for Mucorales 除外)显示出有前景的活性。最初,我们观察到了广泛的 EUCAST MIC 值。在这里,我们更详细地探讨了 MIC 值的可变性,并前瞻性地研究了当代临床霉菌分离株的敏感性,因为未来需要进行流行病学临界值(ECOFF)设置。对 15 株先前发现的 MIC 值较低/中/高(≤0.002 至 0.25 毫克/升)的分离株进行了重复测试,并由三位观察者以盲法方式读取 EUCAST MIC 值。,编码奥洛福米的靶酶二氢乳清酸脱氢酶(DHODH),进行了测序。总共检查了 1423 株霉菌分离株(10 个种复合体[包括 1032 株分离株]和 105 株其他霉菌/皮肤癣菌分离株)。确定了奥洛福米的敏感性(模态 MIC、MIC、MIC 和野生型上限[WT-ULs] [种复合体中≥15 株分离株]),并与四种比较剂进行了比较。MIC 值(毫克/升)在两次 2 倍稀释度(0.016 至 0.03)之间,用于 473/476 次测定。MIC 范围跨越四个稀释度(0.008 至 0.06)。未发现显著的突变。模态 MIC/WT-UL(毫克/升)值为 0.03/0.06(和)、0.06/0.125(和)和 0.06/0.25(和)。的 MIC 范围为 0.008 至 0.25。奥洛福米对唑类耐药和敏感的分离株的敏感性相似,但对和(MIC 值>1)的敏感性降低。随着经验的积累,奥洛福米的药敏试验是可靠的。我们中心分离株的检测显示出均匀的广谱活性。建议使用单中心 WT-ULs。